



Viral Epidemiology Snapshot: August 21-27, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	275	2	0.7%
Flu B	275	0	0.0%
RSV	259	18	6.9%
CoV-2 PUI	1058	222	21.0%
CoV-2 Surveillance	320	10	3.1%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	258	13	5.0%
Coronavirus 229E	258	0	0.0%
Coronavirus HKU1	258	1	0.4%
Coronavirus NL63	258	1	0.4%
Coronavirus OC43	258	0	0.0%
Metapneumovirus	258	2	0.8%
Rhinovirus/Enterovirus	258	98	38.0%
Parainfluenza 1	258	11	4.3%
Parainfluenza 2	258	2	0.8%
Parainfluenza 3	258	1	0.4%
Parainfluenza 4	258	1	0.4%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	0
No Subtype	2
Pending subtype	0

Flu, RSV, & CoV-2 Trends



This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of Feb. '22) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of Oct. '21, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

CoV-2 Positivity Rate Trends

